[ad_1]
GAETAN BALLY
The defendant had “as CEO to be responsible for the business model of the mail order business of certain pharmaceutical products,” a court statement said Tuesday. The mail order pharmacy achieved significant turnover and gained a competitive advantage over the competition.
In addition, zur Rose also violated the Therapeutic Products Act by paying compensation to doctors. In addition to the Thurgau prosecutor’s office, the Swiss pharmacists association PharmaSuisse and the Swiss institute for therapeutic products Swissmedic are also listed as plaintiffs.
The accusation is based on a criminal complaint from PharmaSuisse. Specifically, it was about the shipment of over-the-counter drugs and compensation for doctors who wrote e-prescriptions, Zur Rose wrote last May. The period from 2010 to 2015 is affected.
The public trial against the managing director of Zur Rose begins on December 1 in the district court of Frauenfeld. After that, another eight days of negotiations are planned in January and March 2021.
